Results 111 to 120 of about 15,278 (221)

Estimating population immunity against serotype-two poliomyelitis from the inactivated polio vaccine in routine immunization across 112 countries: A modelling study. [PDF]

PLoS Med
Gray EJ, Cooper LV, Gonzalez AR, Mach O, Derqui N, Grassly NC, Blake IM.   +6 more
europepmc   +1 more source

Intestinal Mucosal Immune Responses to Novel Oral Poliovirus Vaccine Type 2 in Healthy Newborns. [PDF]

Clin Infect Dis
Godin A, Brickley EB, Connor RI, Wieland-Alter WF, Weiner JA, Ackerman ME, Modlin JF, Sajjad OM, Arita M, Gast C, Mainou BA, Zaman K, Hoque M, Rana S, Bandyopadhyay AS, Wright PF.   +15 more
europepmc   +1 more source

Use of killed poliovirus vaccine in a routine immunization program in West Africa [PDF]

, 1984
Evans, A., Maire, Bernard, Parent, Gérard, Salk, D., Schlumberger, M., Stoeckel, P., Van Steenis, G., Van Wezel, A.   +7 more
core   +1 more source

Optimal Disease Eradication [PDF]

Using a dynamic model of the control of an infectious disease, we derive the conditions under which eradication will be optimal. When eradication is feasible, the optimal program requires either a low vaccination rate or eradication.
Michael Hoel, Scott Barrett
core  

Commentary on "Exploring the Phenotypic Profile of Acute Flaccid Paralysis: Insights from a Third-Level Pediatric Emergency Room". [PDF]

Iran J Child Neurol
Hosseinpour S, Ashrafi MR, Heidari M, Parvaneh N, Tavasoli AR.   +4 more
europepmc   +1 more source

Safety of Sabin-Strain Inactivated Poliovirus Vaccine Administered Alone or Concomitantly with Other Vaccines: A Population-Based Post-Marketing Surveillance Study. [PDF]

Vaccines (Basel)
Chang L, Liu Y, Ren Y, Li J, Fang X, Li Y.   +5 more
europepmc   +1 more source

Analysis of vaccination campaign effectiveness and population immunity to support and sustain polio elimination in Nigeria [PDF]

, 2016

core   +1 more source

Progress and gaps in poliovirus immunity: Evidence from a serological survey of children aged 6-23 months in high-risk districts of Pakistan. [PDF]

NPJ Vaccines
Hussain I, Khan A, Umer M, Sajid M, Abbas H, Alam MM, Haq MA, Bosan A, Hafiz R, Partridge J, Soofi S.   +10 more
europepmc   +1 more source

Higher stability of novel live-attenuated oral poliovirus type 2 (nOPV2) despite the emergence of a neurovirulent double recombinant strain in Uganda. [PDF]

Nat Microbiol
Tushabe P, Majumdar M, Carlyle S, Shulman L, Ssekagiri A, Joffret ML, Klapsa D, Cremer J, Arowolo KO, Bujaki E, Bukenya H, EPI Laboratory team, Nanteza MB, Turyahabwe I, Namuwulya P, Birungi M, Eliku JP, Aine F, Tibanagwa M, Nakabazzi L, Gaizi J, Ssebuuma AM, Dhatemwa R, Okia C, Nyachwo M, Nanteza MB, Turyahabwe I, Namuwulya P, Birungi M, Eliku JP, Aine F, Tibanagwa M, Nakabazzi L, Gaizi J, Ssebuuma AM, Dhatemwa R, Okia C, Nyachwo M, Hawes KM, Bakamutumaho B, Duizer E, Bessaud M, Bandyopadhyay AS, Macadam A, Byabamazima CR, Martin J, Bwogi J.   +46 more
europepmc   +1 more source

A national cross-sectional study for poliovirus seroprevalence in the Republic of Korea in 2012: implication for deficiency in immunity to polio among middle-aged people [PDF]

, 2015
Geun-Ryang Bae, Hye-Jin Kim, Ji-Yeon Hyeon, Kwangsook Park, Sang Won Lee, Seoyeon Hwang, Somin Lee, Yong-Seok Jeong, Young Joon Park, Yunhyung Kwon   +9 more
core   +1 more source